ERBB2 and neoplasm: 68Ga-ABY-025 is currently being investigated in a phase II/III clinical trial to determine the correlation between HER2 expression measured with 68Ga-ABY-025 PET and standard histopathology from relevant tumor biopsies (NCT03655353).